Ardelyx, Inc. (ARDX)
$
7.69
-0.16 (-2.08%)
Key metrics
Financial statements
Free cash flow per share
-0.2288
Market cap
1.9 Billion
Price to sales ratio
4.6919
Debt to equity
1.3457
Current ratio
4.4129
Income quality
0.9483
Average inventory
23.7 Million
ROE
-0.3691
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines aimed at treating various gastrointestinal and cardiorenal conditions both in the United States and internationally. The company's lead product candidate, tenapanor, has successfully completed Phase III clinical trials for treating patients suffering from irritable bowel syndrome with constipation and is also undergoing Phase III trials to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD) undergoing dialysis, a condition known as hyperphosphatemia. Ardelyx is additionally developing RDX013, a potassium secretagogue designed to address elevated serum potassium levels, or hyperkalemia, which is particularly relevant for certain patients with kidney or heart disorders. Furthermore, RDX020 is being investigated as an early-stage program targeting metabolic acidosis, a serious electrolyte imbalance affecting patients with CKD. The company has established collaborations with Kyowa Kirin for development in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. for China, and Knight Therapeutics, Inc. in Canada for commercializing tenapanor in those regions. The company's financial metrics show that the EBITDA is -$16,713,000.00 a key indicator of the company's operational profitability, while the gross profit stands at $283,059,000.00 highlighting its earnings from core operations. The weighted average number of diluted shares outstanding is 235,233,000.00 which reflects potential dilution effects, and the company reported depreciation and amortization expenses of $2,063,000.00 illustrating the wear and tear of its assets. Ardelyx’s stock is identified with the symbol 'ARDX' in the market. Investors may find the stock appealing, as it is affordable at $6.21 making it suitable for budget-conscious individuals. The stock boasts a high average trading volume of 4,179,057.00 indicating strong liquidity and interest from the market. With a market capitalization of $1,868,470,060.00 Ardelyx is classified as a small-cap player, which often indicates growth potential. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth in the Healthcare sector. This positioning enhances its ability to attract attention from both investors and collaborators in the field of biopharmaceuticals.
Is Ardelyx, Inc. (ARDX) a good investment?
Investing in Ardelyx, Inc. (ARDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Ardelyx, Inc. (ARDX)'s stock forecast?
Analysts predict Ardelyx, Inc. stock to fluctuate between $3.21 (low) and $8.40 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ardelyx, Inc.'s market capitalization?
As of 2026-01-30, Ardelyx, Inc.'s market cap is $1,868,470,060, based on 242,974,000 outstanding shares.
How does Ardelyx, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Ardelyx, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ardelyx, Inc. (ARDX) stock?
To buy Ardelyx, Inc. (ARDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ARDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Ardelyx, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ardelyx, Inc. stock ever split?
Ardelyx, Inc.'s last stock split was 4:1 on 2021-07-20.
How did Ardelyx, Inc. perform in the last earnings report?
Revenue: $333,615,000 | EPS: -$0.17 | Growth: -43.33%.
Where can I find Ardelyx, Inc.'s investor relations reports?
Visit https://www.ardelyx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ardelyx, Inc.?
You can explore historical data from here
What is the all-time high and low for Ardelyx, Inc. stock?
All-time high: $10.13 (2024-02-12) | All-time low: $0.49 (2022-06-16).
What are the key trends affecting Ardelyx, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults.
zacks.com
Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
seekingalpha.com
Ardelyx has transformed into a commercial powerhouse with two FDA-approved, first-in-class drugs, IBSRELA and XPHOZAH, driving robust revenue growth. IBSRELA's rapid uptake and projected $410–$430 million 2026 revenue, alongside a patent extension to 2041, create a durable, generational asset and significant terminal value. XPHOZAH's $100M+ annual revenue confirms unmet need in hyperphosphatemia, but its slower growth and reimbursement complexity present ongoing risk to the renal franchise.
zacks.com
Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
globenewswire.com
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 92.1% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
Ardelyx (ARDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
seekingalpha.com
Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; management raised 2025 guidance and outlined long-term peak sales targets. ARDX maintains a robust cash position, near-breakeven operations, and strategic patent protection, supporting ongoing commercial and pipeline development.
See all news
